RYVU THERAPEUTICS S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.5 PLN | -0.59% |
|
-5.61% | -12.17% |
| Sales 2024 * | 152M 37.58M | Sales 2025 * | 218M 53.84M | Capitalization | 1.17B 291M |
|---|---|---|---|---|---|
| Net income 2024 * | -161M -39.84M | Net income 2025 * | -119M -29.45M | EV / Sales 2024 * | 7.25 x |
| Net cash position 2024 * | 73.62M 18.22M | Net cash position 2025 * | 27.38M 6.78M | EV / Sales 2025 * | 5.27 x |
| P/E ratio 2024 * |
-12.7
x | P/E ratio 2025 * |
-11.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ryvu Therapeutics S.A.
More press releases
| 1 day | -0.59% | ||
| 1 week | -5.61% | ||
| Current month | -8.51% | ||
| 1 month | -11.09% | ||
| 3 months | -9.82% | ||
| 6 months | -23.72% | ||
| Current year | -12.17% |
1 week
49.55
54.10
1 month
49.5557.30
Current year
49.5561.00
1 year
49.5572.40
3 years
22.2072.40
5 years
22.2078.00
10 years
8.5678.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
| Chief Operating Officer | 38 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 50.5 | -0.59% | 755 |
| 24-04-23 | 50.8 | -0.39% | 5,472 |
| 24-04-22 | 51 | -3.59% | 7,527 |
| 24-04-19 | 52.9 | -0.19% | 4,351 |
| 24-04-18 | 53 | -0.93% | 1,377 |
Delayed Quote Warsaw S.E., April 24, 2024 at 04:35 am EDT
More quotes
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Companyâs portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
50.8
PLN
Average target price
73.12
PLN
Spread / Average Target
+43.95%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.17% | 292M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +3.00% | 22.19B | |
| -16.16% | 21.33B | |
| -7.29% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- RVU Stock
